Saved Results

No results saved yet.

Enter a patient name and hit Save on a result.

Clinical calculator summary

EndoPredict (EPclin) Interpreter

EndoPredict combines a 12-gene molecular score with tumor size and nodal status to generate the EPclin Score.

Evidence-based context for fast calculator use

Purpose:
EndoPredict EPclin Score stratifies early and late distant recurrence risk in ER+/HER2- breast cancer to guide chemotherapy decisions.
Population:
patients undergoing breast cancer risk, staging, pathology, recurrence, or treatment-benefit assessment
Factors:
EPclin Score
Reference:
Filipits M, Rudas M, Jakesz R, et al. A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. Clin Cancer Res. 2011;17(18):6012-6020.
HomeEndoPredict (EPclin) Interpreter
Pin your most used calculators here by clicking the star in the dropdown.

EndoPredict (EPclin) Interpreter

Clinical Context & Background

EndoPredict combines a 12-gene molecular score with tumor size and nodal status to generate the EPclin Score. It is validated to predict the risk of distant recurrence (both 0-10 years and 5-15 years) in ER+, HER2- breast cancer, helping decisions on adjuvant chemotherapy and extended endocrine therapy.
Primary Source EvidenceFilipits M, Rudas M, Jakesz R, et al. A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. Clin Cancer Res. 2011;17(18):6012-6020.
Formula Logic
EPclin Cutoff: 3.3

Reference Data

EPclin ScoreRisk Group10-Year Distant Recurrence Risk
< 3.3Low Risk< 10% (Chemo can typically be omitted)
≥ 3.3High Risk> 10% (Chemo recommended)

Clinical Workflow

Use, Interpret, And Continue The Patient Pathway

Expand for workflow guidance, limitations, examples, and related next steps.

When To Use

  • Use EndoPredict (EPclin) Interpreter when endoPredict EPclin Score stratifies early and late distant recurrence risk in ER+/HER2- breast cancer to guide chemotherapy decisions.
  • Confirm that the patient, diagnosis, disease phase, and available inputs match the cited model before calculation.

How To Interpret

  • Interpret the displayed result using the calculator-specific formula and reference table, spanning < 3.3 through ≥ 3.3.
  • A boundary result should prompt input verification and clinical review rather than false precision.

What To Do Next

  • Integrate the result with invasive versus in-situ status, stage, receptor biology, treatment timing, genomic testing, comorbidity, and patient goals.
  • Document the inputs, result, timing, and clinical context so the assessment can be reproduced.

Limitations

  • Do not interchange screening-risk, DCIS, invasive prognosis, genomic, and post-neoadjuvant tools.
  • The result supports clinician judgment and does not independently determine treatment.

Validated Population

patients undergoing breast cancer risk, staging, pathology, recurrence, or treatment-benefit assessment

How to apply this result

For a representative case, verify EPclin Score, calculate the result, and confirm that its classification matches the highlighted reference band before continuing the disease-specific pathway.

Breast Cancer hubContinue to related calculators and clinical workflow resources.

Share This Calculator

Share:

Related Tools

BI-RADS Score (Breast)Nottingham Prognostic Index (NPI)MSKCC DCIS Nomogram — Breast Cancer DCIS Recurrence Risk Calculator

Frequently Asked Questions

When should EndoPredict (EPclin) Interpreter be used?

Use it for patients undergoing breast cancer risk, staging, pathology, recurrence, or treatment-benefit assessment when all required inputs and the intended clinical setting are confirmed.

Can EndoPredict (EPclin) Interpreter determine treatment by itself?

No. Interpret the result with the cited evidence, complete clinical assessment, current guidelines, and patient-specific goals.

Evidence-based oncology decision support. Verify with clinical guidelines.